Long-acting insulin analogs versus neutral protamine hagedorn insulin and the risk of severe hypoglycemia among patients in type 2 diabetes in the United Kingdom

被引：0
|
作者：
Brunetti, Vanessa C. [1 ]
Filion, Kristian [2 ]
Yu, Oriana Hoi Yun [2 ]
Platt, Robert [2 ]
机构：
[1] McGill, Dept Epidemiol Biostatist & Occupat Hlth, Montreal, PQ, Canada
[2] McGill Univ, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
267
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [31] Long-Acting Insulin Analogs: A Review of "Real-World" Effectiveness in Patients with Type 2 Diabetes
    Pollock, Richard F.
    Erny-Albrecht, Katrina M.
    Kalsekar, Anupama
    Bruhn, David
    Valentine, William J.
    CURRENT DIABETES REVIEWS, 2011, 7 (01) : 61 - 74
  • [32] The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study
    Richeek Pradhan
    Hui Yin
    Oriana H. Y. Yu
    Laurent Azoulay
    Drug Safety, 2020, 43 : 103 - 110
  • [33] The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study
    Pradhan, Richeek
    Yin, Hui
    Yu, Oriana H. Y.
    Azoulay, Laurent
    DRUG SAFETY, 2020, 43 (02) : 103 - 110
  • [34] UTILIZATION PATTERNS AND HYPOGLYCEMIA IN PATIENTS WITH TYPE-2 DIABETES ON CONCOMITANT EXENATIDE AND LONG-ACTING INSULIN THERAPY
    Wade, R.
    Quimbo, R. A.
    Fabunmi, R.
    Blickensderfer, A. L.
    Pawaskar, M. D.
    Misurski, D.
    VALUE IN HEALTH, 2009, 12 (03) : A99 - A99
  • [35] Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update
    Pedersen-Bjergaard, Ulrik
    Fabricius, Therese W.
    Thorsteinsson, Birger
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (16) : 2251 - 2259
  • [36] Efficacy of Rapid-Acting and Long-Acting Insulin Analogs in Japanese Patients with Type 1 Diabetes Mellitus
    Ozaki, Nobuaki
    Nomura, Yoshio
    Wanibe, Harumatsu
    Yamamori, Ikuo
    Oiso, Yutaka
    DIABETES, 2009, 58 : A524 - A524
  • [37] Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes -: A randomized, controlled trial
    Fritsche, A
    Schweitzer, MA
    Häring, HU
    ANNALS OF INTERNAL MEDICINE, 2003, 138 (12) : 952 - 959
  • [38] Healthcare Costs of Long-Acting Insulin Analogs vs NPH Insulin in Type 2 Diabetes Patients Using a Basal Regimen in Denmark
    Gundgaard, Jens
    Aagren, Mark
    Thomsen, Trine L.
    DIABETES, 2009, 58 : A316 - A317
  • [39] Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes
    Rhoads, G. G.
    Dain, M. P.
    Zhang, Q.
    Kennedy, L.
    DIABETES OBESITY & METABOLISM, 2011, 13 (08): : 711 - 717
  • [40] Comparison of Inpatient Insulin Regimens with Detemir plus Aspart Versus Neutral Protamine Hagedorn plus Regular in Medical Patients with Type 2 Diabetes
    Umpierrez, Guillermo E.
    Hor, Tiffany
    Smiley, Dawn
    Temponi, Angel
    Umpierrez, Denise
    Ceron, Miguel
    Munoz, Christina
    Newton, Christopher
    Peng, Limin
    Baldwin, David
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02): : 564 - 569
12345